RxDoctor Payments Data

Nediljka Buljubasic

Cardiovascular Disease · Torrance, CANPI 1063482693

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (48.9%), education and food and beverage — rather than concentrated in one kind of arrangement. Novo Nordisk AS accounts for 61.6% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $1,989 and has fallen 95.9% since, to $81 in 2024. That places this record below the midpoint for cardiovascular disease clinicians in CA, where the typical reported total is $2,142.

$2,683in general payments, 2019–2025

Across 37 payments — averaging $72.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$2K
  • Novo Nordisk$936
  • Scpharmaceuticals Inc.$81
  • Lantheus Medical Imaging, Inc.$13
$468,179in research payments, 2019–2025

Across 434 payments — averaging $1078.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$459K
  • Novartis$9K

What the payments were for

  • Travel & lodging$1,31349%
  • Food & beverage$43416%
  • Education$93635%

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,683 in reported general payments places this provider in the 50th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California →

Other cardiovascular disease in Torrance

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →